City confirms plans for former Merck site to be Celgene campus

The city of Summit (New Jersey, USA) has confirmed that the former Merck campus at 556 Morris Avenue is now contracted to Celgene.

‘Celgene is an exceptional company and a pre-eminent leader in the integrated biopharmaceutical industry that is committed to improving the lives of patients worldwide. The city holds Celgene in high regard for being a longstanding community partner and we anticipate them making the most of an outstanding property,’ said Summit's Mayoress, Ellen Dickson.

‘It is an exciting prospect that Celgene will continue to develop and grow its highly successful business in this world-class Summit location,’ she added.

The search for a purchaser for the campus has been under way since Merck announced plans in October 2013 to move its global headquarters to Kenilworth. ‘This agreement is the result of considerable efforts by the mayor and council,’ said Common Council President Dr Robert Rubino.

‘We are extremely pleased that our work to create a business-friendly environment for our largest corporate citizen has resulted in Celgene reinvesting and expanding here in Summit. As Celgene continues to develop its role as an integral investor in our community, more jobs will be created locally and our downtown and area businesses will benefit as well. This is a win for both the city and Celgene, and a clear indication that Summit is a great place to do business,’ he said.

The site includes research and development facilities, laboratory and support buildings, manufacturing capabilities, storage, warehouse buildings and administrative office space. The site has approximately 850,000 square feet of administrative office space and 450,000 square feet of R&D space. Further information on when and how the campus will be utilised by Celgene will be provided by Summit as it becomes available during the next few months.